Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy

The in vivoanticancer efficacy of nanoparticle-mediated drug delivery depends on the association between the drug and its carrier. Here, the authors use FRET to show that the drug hydrophobicity, and miscibility with the carrier, influence nanoparticle accumulation in murine tumour models.

Guardado en:

Detalles Bibliográficos
Autores principales:	Yiming Zhao, François Fay, Sjoerd Hak, Jose Manuel Perez-Aguilar, Brenda L. Sanchez-Gaytan, Brandon Goode, Raphaël Duivenvoorden, Catharina de Lange Davies, Astrid Bjørkøy, Harel Weinstein, Zahi A. Fayad, Carlos Pérez-Medina, Willem J. M. Mulder
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2016
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/d90fceee65ae4c4ca9f5fa1e73acfa06
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d90fceee65ae4c4ca9f5fa1e73acfa06
record_format	dspace
spelling	oai:doaj.org-article:d90fceee65ae4c4ca9f5fa1e73acfa062021-12-02T14:38:56ZAugmenting drug–carrier compatibility improves tumour nanotherapy efficacy10.1038/ncomms112212041-1723https://doaj.org/article/d90fceee65ae4c4ca9f5fa1e73acfa062016-04-01T00:00:00Zhttps://doi.org/10.1038/ncomms11221https://doaj.org/toc/2041-1723The in vivoanticancer efficacy of nanoparticle-mediated drug delivery depends on the association between the drug and its carrier. Here, the authors use FRET to show that the drug hydrophobicity, and miscibility with the carrier, influence nanoparticle accumulation in murine tumour models.Yiming ZhaoFrançois FaySjoerd HakJose Manuel Perez-AguilarBrenda L. Sanchez-GaytanBrandon GoodeRaphaël DuivenvoordenCatharina de Lange DaviesAstrid BjørkøyHarel WeinsteinZahi A. FayadCarlos Pérez-MedinaWillem J. M. MulderNature PortfolioarticleScienceQENNature Communications, Vol 7, Iss 1, Pp 1-11 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Yiming Zhao François Fay Sjoerd Hak Jose Manuel Perez-Aguilar Brenda L. Sanchez-Gaytan Brandon Goode Raphaël Duivenvoorden Catharina de Lange Davies Astrid Bjørkøy Harel Weinstein Zahi A. Fayad Carlos Pérez-Medina Willem J. M. Mulder Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
description	The in vivoanticancer efficacy of nanoparticle-mediated drug delivery depends on the association between the drug and its carrier. Here, the authors use FRET to show that the drug hydrophobicity, and miscibility with the carrier, influence nanoparticle accumulation in murine tumour models.
format	article
author	Yiming Zhao François Fay Sjoerd Hak Jose Manuel Perez-Aguilar Brenda L. Sanchez-Gaytan Brandon Goode Raphaël Duivenvoorden Catharina de Lange Davies Astrid Bjørkøy Harel Weinstein Zahi A. Fayad Carlos Pérez-Medina Willem J. M. Mulder
author_facet	Yiming Zhao François Fay Sjoerd Hak Jose Manuel Perez-Aguilar Brenda L. Sanchez-Gaytan Brandon Goode Raphaël Duivenvoorden Catharina de Lange Davies Astrid Bjørkøy Harel Weinstein Zahi A. Fayad Carlos Pérez-Medina Willem J. M. Mulder
author_sort	Yiming Zhao
title	Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
title_short	Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
title_full	Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
title_fullStr	Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
title_full_unstemmed	Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
title_sort	augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
publisher	Nature Portfolio
publishDate	2016
url	https://doaj.org/article/d90fceee65ae4c4ca9f5fa1e73acfa06
work_keys_str_mv	AT yimingzhao augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy AT francoisfay augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy AT sjoerdhak augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy AT josemanuelperezaguilar augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy AT brendalsanchezgaytan augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy AT brandongoode augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy AT raphaelduivenvoorden augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy AT catharinadelangedavies augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy AT astridbjørkøy augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy AT harelweinstein augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy AT zahiafayad augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy AT carlosperezmedina augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy AT willemjmmulder augmentingdrugcarriercompatibilityimprovestumournanotherapyefficacy
_version_	1718390800999514112

Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy

Ejemplares similares